| Date | Title | | | 11/20/07 | MannKind to Present at the Piper Jaffray Healthcare Conference| VALENCIA, Calif., Nov. 20 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
the Piper Jaffray Healthcare Conference on November 27, 2007 at 10:30 AM ET at
the Pierre Hotel in New York, NY.
Interested parties can access a link to the live web cast of the
presentation in the Investor Relations section of the Company's website at
http://www.m... |
|  | | 11/07/07 | MannKind Corporation Reports Third Quarter Financial Results| - Conference Call Today at 8:00 a.m. ET -
VALENCIA, Calif., Nov. 7 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) today reported financial results for the third quarter ended
September 30, 2007.
For the third quarter of 2007, total operating expenses were
$75.6 million, compared to $61.1 million for the third quarter of 2006. A
substantial portion of this increase was attributed to increased research and
development (R&D) expenses which totaled $6... |
| | | 11/05/07 | MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation| VALENCIA, Calif., Nov. 5 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) today announced results from a Phase 1a clinical evaluation of
MKC253, a formulation of GLP-1 (glucagon-like peptide) on Technosphere
particles that is delivered using the Company's proprietary inhaler. The
study was designed as an open-label, dose escalation, controlled safety and
tolerability trial, involving 26 healthy, adult, male subjects. Each subject
was assigned to one of five dose levels o... |
| | | 11/05/07 | MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 7, 2007| VALENCIA, Calif., Nov. 5 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) will release its 2007 third quarter financial results on
Wednesday, November 7, 2007 at 6:00 a.m. ET.
Management of the Company will host a conference call to discuss the third
quarter financial results, clinical progress and other Company developments at
8:00 a.m. ET on Wednesday, November 7, 2007. Presenting from the Company will
be its Chairman and Chief Executive Officer, Alfred Mann; Preside... |
| | | 11/01/07 | MannKind to Present at Upcoming Conferences| VALENCIA, Calif., Nov 01, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
the following conferences:
The Acumen BioFin Rodman & Renshaw 9th Annual Healthcare conference on
Tuesday November 6, 2007 at 2:20 PM ET at the New York Palace Hotel in
New York, NY.
The CIBC 18th Annual Healthcare Conferen... |
| | | 10/02/07 | MannKind Announces New $350 Million Credit Facility|
Brings Total Financing Commitments Announced Today to $600 Million
New Commitments Expected To Fund Operations Through Third Quarter of 2009
VALENCIA, Calif., Oct. 2 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) announced today that it has entered into a new loan arrangement
with Alfred E. Mann, its principal stockholder, Chief Executive Officer and
Chairman of the Board of Directors, providing for $350 million in credit
available until December 31, 2009. ... |
| | | 10/02/07 | MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock| VALENCIA, Calif., Oct. 2 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) announced today that it has agreed to sell a total of
27,014,686 shares of its common stock in registered direct offerings to Alfred
E. Mann, its principal stockholder, Chief Executive Officer and Chairman of
the Board of Directors, and to two groups of investors, including accounts
managed by Legg Mason Capital Management, Inc. Of the offered shares,
15,940,489 shares were sold to Mr. Mann at a pri... |
| | | 09/18/07 | MannKind to Present at the UBS Global Life Sciences Conference| VALENCIA, Calif., Sept. 18 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
the UBS Global Life Sciences Conference on September 25, 2007 at 10:30 AM ET
at the Grand Hyatt Hotel in New York, NY.
Interested parties can access a link to the live web cast of the
presentation in the Investor Relations section of the Company's website at
http:... |
| | | 08/09/07 | MannKind Corporation Reports Second Quarter Financial Results| - Conference Call Today at 5:00 p.m. ET -
VALENCIA, Calif., Aug. 9 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) today reported financial results for the second quarter ended
June 30, 2007.
For the second quarter of 2007, total operating expenses were
$75.4 million, compared to $55.8 million for the second quarter of 2006. A
substantial portion of this increase was attributed to increased research and
development (R&D) expenses which totaled $61.... |
| | | 08/08/07 | MannKind Second Quarter Financial Results Conference Call on August 9, 2007| VALENCIA, Calif., Aug. 8 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) will release its 2007 second quarter financial results on
Thursday, August 9, 2007 after the close of the financial markets.
Management of the Company will host a conference call to discuss the
second quarter financial results and other Company developments at 5:00 p.m.
ET on Thursday, August 9, 2007. Presenting from the Company will be its
Chairman and Chief Executive Officer, Alfred Mann; Presi... |
| | | 08/02/07 | MannKind to Hold Investor Call Tomorrow; 2Q Release Next Week| VALENCIA, Calif., Aug. 2 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) announced today that it is moving the release of its 2007
second quarter financial results to Thursday, August 9, 2007. The earnings
release has been moved due to the fact that the Company is continuing its
review of the financial results for the second quarter and six months ended
June 30, 2007. At this time, the Company is reporting that its cash, cash
equivalents and marketable securities were $28... |
| | | 07/26/07 | MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 3, 2007| VALENCIA, Calif., July 26 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) will release its 2007 second quarter financial results on
Friday, August 3, 2007 at 7:00 a.m. ET.
Management of the Company will host a conference call to discuss the
second quarter financial results, clinical progress and other Company
developments at 9:00 a.m. ET on Friday, August 3, 2007. Presenting from the
Company will be its Chairman and Chief Executive Officer, Alfred Mann;
President and... |
| | | 06/15/07 | MannKind Resolves Litigation With Former Employee| VALENCIA, Calif., June 15 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) announced today that it has reached a final resolution in the
civil litigation filed by its former Chief Medical Officer, Dr. Wayman Wendell
Cheatham.
Dr. Cheatham filed a Complaint in May 2005, alleging causes of action for
wrongful termination in violation of public policy and breach of contract,
following the termination of Dr. Cheatham's employment on May 2, 2005. A
trial on these matters ... |
| | | 06/07/07 | MannKind to Present at the Needham & Company Biotechnology & Medical Technology Conference| VALENCIA, Calif., June 7 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
the Needham & Company Biotechnology & Medical Technology Conference on
June 13, 2007 at 9:30 AM ET at the New York Palace Hotel in New York, NY.
Interested parties can access a link to the live web cast of the
presentation in the Investor Relations section of the Com... |
| | | 05/24/07 | MannKind to Present at the Bank of America 2007 Health Care Conference| VALENCIA, Calif., May 24 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
the Bank of America 2007 Health Care Conference on May 31, 2007 at 2:40 PM PT
at the Four Seasons Hotel in Las Vegas, Nevada.
Interested parties can access a link to the live web cast of the
presentation in the Investor Relations section of the Company's website at
... |
| | | 05/11/07 | MannKind Corporation Reports First Quarter Financial Results| - Conference Call Today at 9:00 a.m. EDT -
VALENCIA, Calif., May 11 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) today reported financial results for the first quarter ended
March 31, 2007.
For the first quarter of 2007, total operating expenses were $77.3
million, compared with $45.1 million for the first quarter of 2006. A
substantial proportion of this increase was attributed to increased research
and development (R&D) expenses which were $63... |
| | | 05/07/07 | MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 11, 2007| VALENCIA, Calif., May 7 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) will release its 2007 first quarter financial results on
Friday, May 11, 2007 at 7:00 a.m. EDT.
Management of the Company will host a conference call to discuss the first
quarter financial results, clinical progress and other Company developments at
9:00 a.m. EDT on Friday, May 11, 2007. Presenting from the Company will be
its Chairman and Chief Executive Officer, Alfred Mann; President and Chief... |
| | | 05/04/07 | MannKind to Present at the UBS Global Generic and Specialty Pharmaceuticals Conference| VALENCIA, Calif., May 4 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
the UBS Global Generic and Specialty Pharmaceuticals Conference on May 8, 2007
at 12:30 PM EDT at the Grand Hyatt Hotel in New York, NY.
Interested parties can access a link to the live web cast of the
presentation in the Investor Relations section of the Company's we... |
| | | 04/04/07 | MannKind to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference| VALENCIA, Calif., April 4, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals
Conference on April 11, 2007 at 10:20 AM (EDT) at the Millennium Broadway
Hotel in New York, NY.
Interested parties can access a link to the live web cast of the
presentat... |
| | | 03/05/07 | MannKind to Present at Cowen and Company 27th Annual Health Care Conference| VALENCIA, Calif., March 5, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
the Cowen and Company 27th Annual Health Care Conference on March 12, 2007 at
3:10 PM (EDT) at The Boston Marriott Copley Place in Boston, Massachusetts.
Interested parties can access a link to the live web cast of the
presentation in the Inves... |
| | | 02/02/07 | MannKind Corporation Reports Fourth Quarter and Full Year 2006 Financial Results| - Conference Call to Begin Today at 9:00 a.m. ET -
VALENCIA, Calif., Feb. 2 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) today reported financial results for the fourth quarter and
year ended December 31, 2006.
For the fourth quarter of 2006, total operating expenses were
$71.8 million, compared with $35.0 million for the fourth quarter of 2005.
Research and development (R&D) expenses increased by $31.2 million to
$59.7 million for the fourth quarter of 200... |
| | | 02/01/07 | Frost & Sullivan Acknowledges MannKind's Path-Breaking Solution to Treat Diabetes| PALO ALTO, Calif. and VALENCIA, Calif., Feb 01, 2007 /PRNewswire via COMTEX News Network/ -- Frost &
Sullivan selected MannKind Corporation (Nasdaq: MNKD) as the recipient of the
2006 Frost & Sullivan Award for Product Innovation for its lead product, the
Technosphere(R) Insulin System. By focusing on inhaled insulin development, a
high profile and underserved area of diabetes therapy, MannKind has
established itself as a leader in product innovation for diabetes.
To choose the recipient ... |
| | | 01/31/07 | MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 2, 2007| VALENCIA, Calif., Jan. 31 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) will release its 2006 fourth quarter financial results on
Friday, February 2, 2007 at 7:00 a.m. EST.
Management of the Company will host a conference call to discuss the
fourth quarter financial results, clinical progress and other Company
developments at 9:00 a.m. EST on Friday, February 2, 2007. Presenting from
the Company will be its Chairman and Chief Executive Officer, Alfred Mann;
Corpor... |
| | | 01/30/07 | MannKind to Present at Leerink Swann & Company Diabetes Roundtable Conference| VALENCIA, Calif., Jan 30, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
the Leerink Swann & Company Diabetes Roundtable Conference on February 5, 2007
at 8:45 AM (EST) at the Le Parker Meridien in New York City.
Interested parties can access a link to the live web cast of the
presentation in the Investor Relations s... |
| | | 01/12/07 | MannKind to Present at Upcoming Healthcare Conferences|
VisionGain 3rd Annual Strategic Forum - January 18, 2007 at 2:00 pm (GMT)
Wachovia Securities 2007 Healthcare Conference - January 30, 2007 at
1:30 pm (EST)
Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device
Conference - February 7, 2007 at 9:20 am (EST)
VALENCIA, Calif., Jan. 12 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
trea... |
| | | 01/02/07 | MannKind to Present at 25th Annual JPMorgan Healthcare Conference| VALENCIA, Calif., Jan. 2 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
the 25th Annual JPMorgan Healthcare Conference on January 9, 2007 at 12:00 pm
(PST) in San Francisco to provide an update on the Company.
Interested parties can access a link to the live web cast of the
presentation in the Investor Relations section of the Company's ... |
| |
|
Print | 
E-mail Page | 
RSS Feeds | 
E-mail Alerts | 
IR Contacts | 
Tear Sheet
